TL;DR
This study investigates the complex mechanisms behind multidrug resistance (MDR) in breast cancer cells, moving beyond the known role of ABCG2. Using a novel AmpArray technique, researchers identified 15 additional ABC transporters that are significantly overexpressed in resistant cells, suggesting a multi-transporter contribution to MDR. This work highlights the potential of AmpArray as a rapid diagnostic tool for personalized cancer therapy.
What Problem Does This Paper Address?
Multidrug resistance (MDR) is a major hurdle in effective cancer chemotherapy, leading to treatment failure. While the overexpression of certain ATP-binding cassette (ABC) transporters, like ABCB1 (P-glycoprotein) and ABCC1 (MRP1), is a known contributor to MDR, the exact mechanisms in all resistant cell lines are not fully understood. Specifically, a drug-resistant breast cancer cell line, MCF7/AdVp3000, exhibits a much higher level of resistance than can be explained by the previously identified overexpression of ABCG2 alone. This discrepancy suggests that other ABC transporters might also be involved in conferring this resistance. The paper aims to comprehensively profile the expression of a wide range of ABC transporters in this resistant cell line to identify other potential players in MDR.
Methods
The core of this study's methodology lies in the AmpArray technique, a custom-designed PCR-based assay for profiling the expression of multiple ABC transporter genes simultaneously. This approach utilizes a 96-well plate format with pre-designed primer pairs for 47 human ABC transporters (excluding ABCE1 and ABCF1, which lack transmembrane domains) and a GAPDH control. The AmpArray provides a semiquantitative measure of gene expression by analyzing PCR product intensity on an agarose gel.
To validate the AmpArray findings and provide more precise quantification, real-time quantitative RT-PCR (RT-qPCR) was employed. This method uses SYBR Green and a thermal cycler to measure fluorescence, allowing for more accurate determination of mRNA levels. Different primer sets were used for RT-qPCR to ensure the robustness of the findings.
Furthermore, Western blot analysis was used to confirm the protein expression levels of key identified ABC transporters (ABCG2 and ABCC3) in cell lysates and plasma membranes. This step is crucial because mRNA expression does not always directly correlate with protein abundance.
Finally, to assess the functional contribution of a specific transporter (ABCC3) to drug resistance, siRNA-mediated gene silencing was performed. The effect of ABCC3 knockdown on doxorubicin resistance was then evaluated using a sulforhodamine B (SRB) colorimetric assay, which measures cell viability.
Datasets
The study utilized two human breast cancer cell lines:
- MCF7: The parental, drug-sensitive cell line.
- MCF7/AdVp3000: A derivative, drug-resistant cell line selected for resistance to doxorubicin in the presence of verapamil.
- MCF7/AdVpRev: A revertant cell line that has lost ABCG2 overexpression, used to assess the reversibility of transporter expression changes and their link to resistance.
No new datasets were generated or introduced; the study focused on profiling gene expression within these established cell lines.
Key Insights and Ideas
- Multitransporter Contribution to MDR: The most significant insight is that drug resistance in MCF7/AdVp3000 cells is not solely due to ABCG2 but involves the coordinated overexpression of multiple ABC transporters.
- AmpArray as a Rapid Profiling Tool: The study demonstrates the utility of AmpArray as a quick, cost-effective, and semiquantitative method for screening ABC transporter expression in resistant cell lines and potentially in clinical samples.
- ABCC3 as a Key Player: ABCC3 emerged as a particularly important transporter, showing a dramatic ~459-fold increase in expression and a complete reversal in the revertant cell line. Functional studies confirmed its direct contribution to doxorubicin resistance.
- ABCA4 Protein Expression Discrepancy: While ABCA4 mRNA was highly upregulated, protein levels could not be detected, suggesting post-transcriptional regulation or very low protein stability, highlighting the importance of validating mRNA findings at the protein level.
- Reversibility as an Indicator of Functional Relevance: The complete or partial reversal of transporter expression in the revertant cell line (MCF7/AdVpRev) served as a strong indicator of their potential role in conferring drug resistance.
Key Results
- 16 ABC Transporters Altered: The AmpArray identified 16 ABC transporters with ≥1.5-fold altered expression in MCF7/AdVp3000 cells compared to parental MCF7 cells.
- Dramatic Upregulation of ABCA4, ABCC3, and ABCG2: Specifically, ABCA4 showed a ~132-fold increase, ABCC3 a ~459-fold increase, and ABCG2 a ~3000-fold increase in mRNA levels.
- Validation by RT-qPCR: RT-qPCR confirmed the differential expression of most of these 16 genes, with some quantitative differences due to the semiquantitative nature of AmpArray.
- Protein Confirmation: Western blot analysis confirmed the elevated protein levels of ABCC3 and ABCG2 in resistant cells and their decrease in the revertant cell line.
- ABCC3 Silencing Reduces Resistance: Silencing ABCC3 expression using siRNA significantly reduced doxorubicin resistance in MCF7/AdVp3000 cells, directly implicating ABCC3 in this phenotype.
- ABCB1 and ABCC1 Not Upregulated: Notably, ABCB1 and ABCC1, commonly associated with MDR, did not show increased expression in the resistant cell line, consistent with the use of verapamil (an inhibitor of these transporters) during cell line selection.
Limitations and Future Work
- Semiquantitative Nature of AmpArray: The authors acknowledge that AmpArray is semiquantitative, leading to variations in fold-change measurements compared to RT-qPCR. This is particularly evident for genes with small expression changes.
- Insensitivity to Extremely High mRNA Levels: AmpArray was less sensitive in detecting the massive ~3000-fold upregulation of ABCG2, showing only a ~6-fold difference.
- ABCA4 Protein Detection Failure: The inability to detect ABCA4 protein despite high mRNA levels suggests that mRNA expression alone is insufficient and protein-level validation is critical. This points to potential post-transcriptional regulation.
- False Positives/Negatives: The study identified some false positives (e.g., ABCA7, ABCB3) and potential false negatives with AmpArray, underscoring the need for validation.
- Future Work: The authors suggest that AmpArray could be used for profiling ABC transporters in clinical samples to aid in personalized therapy design. Further studies are needed to clone and sequence ABCC3 to investigate potential spontaneous mutations contributing to resistance. Investigating the role of other identified transporters, such as ABCC8, in drug resistance is also warranted.
Summary updated